

Short Name	Comments	Type	Investigator	Contact
<b>Disease site specific</b>				
<b>Newly Diagnosed Glioblastoma Trials</b>				
<b>Meningioma</b>				
NRG-BN003	Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<b>Medulloblastoma</b>				
ACNS0332	COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients. <b>Patients <math>\geq</math> 3 and &lt;22 years at the time of diagnosis</b>  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<b>Registry</b>				
Glioma Registry	Glioma Data Registry for Research  <i>The purpose of this research is to establish an ongoing data collection registry, where a wealth of information provided by patients with gliomas can help future researchers evaluate the practice patterns, as well as pathological and clinical outcomes associated with the treatment of gliomas</i>	Registry	<a href="#">Sherman, Wendy</a>	Nicole Mitchell <a href="mailto:cancer.research@spectrumhealth.org">cancer.research@spectrumhealth.org</a> (616) 486-8500
<b>Glioma Symptom Management</b>				
Alliance A221101	HIGH GRADE GLIOMA/ Cancer Related Fatigue. Treatment: <b><i>Armodafinil</i></b> vs Placebo  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

<b>Protocols that are NOT disease site specific</b>				
<b>Treatment</b>				
<b>Alexion ALXN6000-ONC-102</b>	<b>Alexion Protocol ALXN6000-ONC-102: A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients with Advanced Cancer</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>ALEXO AT148001</b>	<b>Alexo Protocol AT148001: A Phase 1, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
	<b>A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
	<b>A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
	<b>A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) and Other Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>BGB-290</b>	<b>A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554

	<b>A Phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
	<b>A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>SCI-CD47-001</b>	<b>First-in-Human Phase I Dose Escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>ASN002</b>	<b>A Phase I/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>20150195 AMG 820</b>	<b>A Phase Ib/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination with Pembrolizumab in Select Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>R3767-ONC- 1613</b>	<b>A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1-mAb) in Patients with Advanced Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554

<b>CP-MGA012-01</b>	<b>A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>MK-4820</b>	<b>A Phase 1 Trial of MK-4820 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>ASN003-101</b>	<b>A Phase I, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>MK-8353-013</b>	<b>A Phase 1b Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>5F9004</b>	<b>A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>CP-MGA012-01</b>	<b>A Phase 1 Study of the Safety, tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>MK-4280-001</b>	<b>A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>CVM-001</b>	<b>A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients with Advanced Cancer</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554

LZM009-001	A First-in-Human, Multicenter, Open-label, Phase 1 Dose Escalation Study of LZM009 in Subjects with Advanced Solid Tumors	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
APX_CLN_0011	A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
CPI-1205-202	A Phase 1 Study of CPI-1205 with Ipilimumab or Pembrolizumab in Patients with Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 with Ipilimumab or Pembrolizumab in Selected Tumor Types Previously Treated with PD-1 or PD-L1 Inhibitors	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
NRG CC003	Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
A071401	Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<b>Molecular Profiling</b>				
QOL Multisite EAQ-152	EAQ-152 - (COMET MATCH) - A randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

<b>EAY131 - MATCH</b>	<b>MOLECULAR ANALYSIS / ADVANCED REFRACTORY SOLID TUMORS OR LYMPHOMAS; Targeted Therapy Directed by Genetic Testing –</b> See sub-protocols below  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
<b>EAY131</b>	<b><i>Dasatinib</i> in Patients with Tumors with DDR2 Mutations</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
<b>EAY131 - A</b>	<b>Solid Tumors (Other than SC &amp; NSCLC) or Lymphomas; <i>Afatinib</i> in Patients that have Activating Mutations of EGFR and Have Progressed After Standard Treatment</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
<b>EAY131 - B</b>	<b>Tumors with HER2 Activating Mutations; Treatment: <i>Afatinib</i></b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
<b>EAY131 - C1</b>	<b><i>Crizotinib</i> in Patients with Tumors with MET Amplification</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
<b>EAY131 - C2</b>	<b><i>Crizotinib</i> in Patients with Tumors with MET Exon 14 Deletion</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>

EAY131 - E	<b>Tumors Having EGFR T790M Mutations (Except NSCLC) or Rare Activating Mutations of EGFR; Treatment: <u><a href="#">AZD9291</a></u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - F	<b>Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations; Treatment: <u><a href="#">Crizotinib</a></u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - G	<b>ROS1 Translocations (Other Than Patients with NSCLC); Treatment: <u><a href="#">Crizotinib</a></u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - H	<b>Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer); Treatment: <u><a href="#">Dabrafenib</a></u> and <u><a href="#">Trametinib</a></u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - J	<b><u><a href="#">Trametinib</a></u> and <u><a href="#">Pertuzumab</a></u> (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - L	<b>Phase II Study of MLN0128 (<u><a href="#">TAK-228</a></u>) in Patients with Tumors with mTOR Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

EAY131 - M	Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - R	BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations; Treatment: <u>Trametinib</u>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - S1	<u>Trametinib</u> in Patients with Tumors with NF1 Mutations  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - S2	<u>Trametinib</u> in Patients with Tumors with GNAQ or GNA 11 Mutations  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - T	Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations; Treatment: <u>GDC-0449 (vismodegib)</u> <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - V	Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) Treatment: <u>Sunitinib</u>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - W	Phase II Study of <u>AZD4547</u> in Patients with Tumors with Aberrations in the FGFR Pathway  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>



EAY131 - X	<b><u>Dasatinib</u></b> in Patients with Tumors with DDR2 Mutations	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Y	<b><u>AZD5363</u></b> in Patients with Tumors with AKT Mutations	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1A	<b><u>Binimetinib</u></b> in Patients with Tumors (Other than Melanoma) with NRAS Mutations	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1B	<b>MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1D	<b><u>Nivolumab</u></b> in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1E	<b>Testing <u>LOXO-101</u> as Potentially Targeted Treatment in Cancers with NTRK Genetic Changes</b>		<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

<b>EAY131 - Z11</b>	<b>Testing <u>AZD1775</u> as a Possible Treatment in People who have Cancer with BRCA Mutations</b>		<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<b>ASCO TAPUR</b>	<b>Targeted Agent and Profiling Utilization Registry Study. <u>All drugs provided</u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<b>Biorepository</b>				
<b>NCI PDM 9846</b>	<b>Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)</b>	Biobanking	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<b>SHARE</b>	<b>The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High, Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators</b>	Biobanking	Cottingham, Sandra	Spectrum Health Biorepository <a href="mailto:david.chesla@spectrumhealth.org">david.chesla@spectrumhealth.org</a> (616) 267-2629
	<i>This study will collect high-quality biologic specimens including tumor/diseased tissue, matched normal tissue, bodily fluids, and correlating health information from patients with the diagnosis of neoplasm or other conditions and related data for use in laboratory research.</i>			
<b>Assessment/ Education</b>				
<b>URCC 13059 GAP-70</b>	<b>Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer: Reducing Chemotherapy Toxicity in Older Adults</b>	Other	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

---

*Symptom Management*


---

<b>S1415CD</b>	<b>A Pragmatic Trial To Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)</b>	Symptom Management	<a href="#">CRCWM</a> <a href="#">Physician</a> <a href="#">Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				
<b>URCC 04040 YOCAS</b>	<b>A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors</b>	Symptom Management	<a href="#">CRCWM</a> <a href="#">Physician</a> <a href="#">Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				
<b>URCC 16070</b>	<b>Treatment of Refractory Nausea</b>	Symptom Management	<a href="#">CRCWM</a> <a href="#">Physician</a> <a href="#">Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				